gynecomastia/diarree

De link wordt op het klembord opgeslagen

Kies het sorteertype

Bladzijde 1 van 28 resultaten

Index of suspicion. Case 1: abdominal pain, distension, hard stool, and diarrhea in an 11-year-old boy. Case 2: recurrent otitis media in a 4-year-old boy. Case 3: gynecomastia and galactorrhea in a 15-year-old boy.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

[Influence of size and duration of gynecomastia on its response to treatment with tamoxifen].

Alleen geregistreerde gebruikers kunnen artikelen vertalen

BACKGROUND Gynecomastia is treated when it is painful, there are psychosocial repercussions or it does not revert in less than two years. It is treated with the antiestrogenic drug tamoxifen, but there are doubts about its effectiveness in high volume gynecomastias or in those lasting more than two

A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

OBJECTIVE The objective of this study was to evaluate efficacy, safety, and dose-response profiles of four dosing schemes of flutamide over 24 weeks. METHODS Patients were randomized to receive one of the following five treatment regimens for a period of 24 weeks: placebo capsule, flutamide capsules

Clinical response to busramustine (KM-2210) in chronic lymphocytic leukemia: a pilot evaluation of estrogen receptor in relation to its therapeutic effect.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

Busramustine (KM-2210), the benzoate of a 17 beta-estradiol-chlorambucil conjugate, was administered to 11 patients with chronic lymphocytic leukemia (CLL) which included eight cases of B-cell CLL and three cases of T-cell CLL. Four patients had received prior chemotherapy. Busramustine was given

Goserelin acetate implant: a depot luteinizing hormone-releasing hormone analog for advanced prostate cancer.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

Goserelin acetate implant is a newly approved depot formulation of a luteinizing hormone-releasing hormone (LHRH) agonist indicated for palliation of advanced prostate cancer. LHRH superagonists suppress gonadotropin release from the pituitary gland by causing down-regulation of receptors. The

Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

OBJECTIVE Androgen ablation with luteinizing hormone-releasing hormone (LHRH) agonists, orchiectomy, or oral estrogens has significant untoward sexual side effects. We evaluated a combination of finasteride and flutamide as potency-sparing androgen ablative therapy (AAT) for advanced adenocarcinoma

Flutamide monotherapy as primary treatment in advanced prostatic carcinoma.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

Little is known about the efficacy of flutamide monotherapy in previously untreated patients with prostatic carcinoma. In this study, 40 patients with advanced disease were treated with 250 mg flutamide, three times daily. The mean follow-up was 7 months. After 3 months, 35 patients were evaluable

Problems associated with medical treatment of peptic ulcer disease.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

In the United States, the drugs most commonly used to treat peptic ulcer disease are antacids and the H2-receptor antagonists cimetidine and ranitidine. Other available agents include anticholinergics and the coating agent sucralfate. Investigational drugs such as colloidal bismuth, carbenoxolone,

Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

BACKGROUND The treatment for prostate cancer patients with biochemical failure after local therapy remains controversial. Peripheral androgen blockade using a combination of a 5-alpha reductase inhibitor and an antiandrogen may allow control of the prostate-specific antigen (PSA). Because

Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

OBJECTIVE To compare in a randomized clinical trial the therapeutic efficacy of the nonsteroidal antiandrogen flutamide 250 mg tid to testicular androgen suppression by orchidectomy in patients with metastatic prostate cancer. METHODS Between 1989 and 1991, 104 patients aged 74 +/- 8 years with

[The role of bicalutamide in the treatment of prostate cancer].

Alleen geregistreerde gebruikers kunnen artikelen vertalen

Bicalutamide is an effective, non-steroidal antiandrogen, suitable for oral, once daily administration. Bicalutamide 50 mg plus LHRHa is at least as effective as flutamide plus LHRHa in terms of survival and time to progression. Monotherapy with bicalutamide 150 mg once daily has similar survival

Hormonal treatment for prostate cancer in Italy. Preliminary data from a survey of the QUABIOS Group.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

OBJECTIVE An observational study was planned by the QUABIOS group, to survey the hormonal modalities administered to prostate cancer patients in Italy within a time window of 12 months. We report here a summary of treatment schedules and related adverse effects, as recorded at the first

Efficacy and tolerability of Casodex in patients with advanced prostate cancer. International Casodex Study Group.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

The efficacy and tolerability of Casodex, a new non-steroidal antiandrogen, were studied in 267 patients with advanced prostate cancer. All patients received Casodex, 50 mg daily, as monotherapy. The objective response rate was 55.5% and the subjective response rate was 56.1%. The most common

Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

OBJECTIVE The safety, efficacy, and pharmacokinetics of the nonsteroidal antiandrogen bicalutamide were investigated in a Phase II trial in 150 patients with metastatic prostate cancer. METHODS Patients took bicalutamide, 50 mg daily, in an open-label multicenter North American trial. RESULTS The

Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

OBJECTIVE PC-SPES is an herbal supplement for which there are anecdotal reports of anti-prostate cancer activity. This phase II study was undertaken to assess the efficacy and toxicity of PC-SPES in prostate cancer patients. METHODS Thirty-three patients with androgen-dependent prostate cancer

Vorige
1
2
De volgende

Word lid van onze
facebookpagina

Herbal & Natural Medicine

De meest complete database met geneeskrachtige kruiden, ondersteund door de wetenschap

Werkt in 55 talen
Kruidengeneesmiddelen gesteund door de wetenschap
Kruidenherkenning door beeld
Interactieve GPS-kaart - tag kruiden op locatie (binnenkort beschikbaar)
Lees wetenschappelijke publicaties met betrekking tot uw zoekopdracht
Zoek medicinale kruiden op hun effecten
Organiseer uw interesses en blijf op de hoogte van nieuwsonderzoek, klinische onderzoeken en patenten

Typ een symptoom of een ziekte en lees over kruiden die kunnen helpen, typ een kruid en zie ziekten en symptomen waartegen het wordt gebruikt.
* Alle informatie is gebaseerd op gepubliceerd wetenschappelijk onderzoek